logo

UK News

Share SHARE

Pharmacompanies-111717.jpg If the timeline is adhered to, this clinical-stage company, focused on developing drugs for disorders concerned especially with the ear, nose, and throat, has an important catalyst coming up this quarter.

sharessubdued-111717.jpg European stocks were subdued on Friday as the euro strengthened against the dollar and investors digested comments by ECB President Mario Draghi at the Frankfurt European Banking Congress. The pan-European Stoxx Europe 600 index was down 0.3 percent at 383.89 in late opening deals after rising 0.8...

marketmixed-111717.jpg European stocks may open on a mixed note on Friday as U.S. tax cuts move closer to passage. It is a "big win", U.S. President Donald Trump tweeted after the GOP plan for tax reform overhaul cleared the House Thursday in a sweeping victory for the Republican leadership. The tax debate now moves to...

Pharma-111717.jpg Today's Daily Dose brings you news about Aerie's progress in phase II trial of glaucoma drug in Japan; phase III results of Egalet's pain pill; FDA approval of GlaxoSmithKline's COPD drug; expanded labeling for Pfizer's kidney cancer drug Sutent and Roche's double blessing on Thursday.

Nov16-111617.jpg The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of November 16, 2017.

Retailsales-UK-111617.jpg UK retail sales grew only moderately in October on weak food and clothing demand, the Office for National Statistics reported Thursday. Retail sales increased 0.3 percent in October from September, but slightly faster than the expected 0.2 percent and reversed the 0.7 percent drop seen in September.

Carney-BoE-111617.jpg The Bank of England stands ready to support the UK economy during the Brexit transition period irrespective of whether the government strikes a deal with the European Union, the bank's chief Mark Carney said Thursday. "We will do whatever we can to support the economy during the transition... - whether...

sharehigher3-111617.jpg European stocks rebounded after recent losses on Thursday as oil held steady, the dollar bounced back from four-week lows and investors kept an eye on U.S. tax reform developments. The day's economic reports proved to be a mixed bag, with Eurozone inflation slowing slightly as initially estimated...

stockhigh-111617.jpg European stocks look set to open a tad higher on Thursday despite U.S. stock markets ending lower for a second straight session overnight in the wake of further declines in oil prices and the release of mixed readings on inflation, retail sales and manufacturing. Asian stocks are trading mostly higher...

pharma-111617.jpg Today's Daily Dose brings you news about FDA approval of Faslodex-Verzenio combo for advanced breast cancer; EDAP's disappointing Q3 results; upcoming clinical trial catalysts of TapImmune, and the first drug to be greenlighted for Sly syndrome.

Nov15-111517.jpg The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of November 15, 2017.

Unemployment-UK-111517.jpg The UK unemployment rate held steady at the lowest since 1975 but employment decreased in the third quarter. The ILO jobless rate came in at 4.3 percent in the third quarter, the same as in three months to August, the Office for National Statistics said Wednesday.

stockdecline-111517.jpg European stocks extended losses from the previous session to reach an eight-week low on Wednesday as a surging euro and weak commodity prices on concerns over slowing Chinese growth sapped investor appetite for risk. The pan-European Stoxx Europe 600 was down 0.8 percent at 380.83 in late opening...

Pharma-111517.jpg Today's Daily Dose brings you news about Apollo Medical's fiscal 2018 second quarter financial results; FDA approval of AstraZeneca's asthma drug; EyeGate's upcoming clinical trial catalysts; Genmab's revised revenue outlook and Pacira's update on its EXPAREL sNDA.

stocklower-111517.jpg European stocks may open on a subdued note on Wednesday as investors keep an eye on oil price movements and the upcoming vote on the U.S Republican tax reform bill. House Speaker Paul Ryan on Tuesday described the current plans as a "work in progress" and didn't rule out changes to the bill ahead...

Follow RTT